However, within certain high-risk areas or high-risk populations (e.g., Taiwan), the implementation of screening is conceivable, and the improved cost-effectiveness of a duplexed IgA and IgG detection may contribute to the feasibility of NPC screening implementation based on several EBV IgA and IgG antibodies [27]. The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.